Compare BSVN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | RLMD |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.3M | 461.9M |
| IPO Year | 2018 | 2012 |
| Metric | BSVN | RLMD |
|---|---|---|
| Price | $58.63 | $3.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $63.33 | $10.75 |
| AVG Volume (30 Days) | 34.4K | ★ 1.4M |
| Earning Date | 10-15-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ 2.12 | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $54.28 | N/A |
| P/E Ratio | $27.71 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $38.29 | $2.15 |
| 52 Week High | $59.04 | $8.00 |
| Indicator | BSVN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 69.33 | 39.10 |
| Support Level | $53.85 | $3.13 |
| Resistance Level | N/A | $3.55 |
| Average True Range (ATR) | 1.08 | 0.21 |
| MACD | 0.28 | 0.03 |
| Stochastic Oscillator | 99.34 | 39.57 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.